As of Nov 19, 2026, 1 of 1 active firms rate ENSC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ENSC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.01
Range $-0.01 – $-0.01 · 1 analysts · -98% YoY
Next period, 1 analysts expect Ensysce Biosciences Inc to earn $-0.01 a share (range $-0.01 – $-0.01), versus $-0.52 a year earlier. Full-year consensus is $-0.23, growing to $-0.05 the year after.
REVENUE · NEXT QUARTER
$1.2M
Range $1.2M – $1.2M · 1 analysts · +25% YoY
Revenue is expected to reach $1.2M (range $1.2M – $1.2M), +24.9% year-over-year. Full-year consensus is $5.5M, rising to $2.8M next year.
Top analysts covering Ensysce Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ENSC.
#1
OB
Olivia Brayer Saunders
Cantor Fitzgerald
Buy
$2.00+440.1% to target
Coverage
—
+ Follow
ENSC stock forecast FAQ
What is ENSC's average 12-month price target?+
The 1 active firms with a live target average $2.00 for Ensysce Biosciences Inc over the next 12 months, ranging from a $2.00 high to a $2.00 low, as of Nov 19, 2026.
Is ENSC stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover ENSC?+
1 active firms have a recognized rating on Ensysce Biosciences Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ENSC?+
Among analysts who currently cover ENSC, Olivia Brayer Saunders of Cantor Fitzgerald has the strongest overall Quantellect track record. Their current call is Buy with a $2.00 target.
What is Ensysce Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.01 per share (range $-0.01 – $-0.01) across 1 analysts. Full-year EPS is projected at $-0.23, rising to $-0.05 the following year.
How much revenue is Ensysce Biosciences Inc expected to report next quarter?+
Consensus revenue is $1.2M (range $1.2M – $1.2M). Full-year revenue is projected at $5.5M, growing to $2.8M next year.
Have analysts been upgrading or downgrading ENSC lately?+
As of Nov 19, 2026, 1 of 1 active firms rate ENSC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ENSC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.